uk
us
de
Scibase
  • MELANOMA
    • INDICATION FOR USE
    • MELANOMA
    • HOW TO MEASURE
    • THE EIS TECHNOLOGY
    • CLINICAL STUDIES
    • CLINICAL BENEFITS
    • RESEARCH MILESTONES
    • PUBLICATIONS
  • FOR PATIENTS
    • SKIN CANCER INFORMATION
    • FIND CLINICS
    • SELF EXAMINATION
    • PATIENT ORGANIZATIONS
    • PATIENT LABELING
  • SCIBASE
    • ABOUT SCIBASE
    • AVAILABLE MARKETS
    • WE ARE SCIBASE
    • NEWS & EVENTS
    • CEO-LETTERS
  • INVESTORS
  • CONTACT US
  • MELANOMA
    • INDICATION FOR USE
    • MELANOMA
    • HOW TO MEASURE
    • THE EIS TECHNOLOGY
    • CLINICAL STUDIES
    • CLINICAL BENEFITS
    • RESEARCH MILESTONES
    • PUBLICATIONS
  • FOR PATIENTS
    • SKIN CANCER INFORMATION
    • FIND CLINICS
    • SELF EXAMINATION
    • PATIENT ORGANIZATIONS
    • PATIENT LABELING
  • SCIBASE
    • ABOUT SCIBASE
    • AVAILABLE MARKETS
    • WE ARE SCIBASE
    • NEWS & EVENTS
    • CEO-LETTERS
  • INVESTORS
  • CONTACT US
uk
us
de

Leading developer of augmented intelligence-based solutions for skin disorders

CEO-LETTERS

Simon Grant, CEO of Scibase, shares his knowledge and perspectives ;

 

CEO Letter 9 – January 2022

CEO Letter 8 – September 2020

CEO Letter 7 – July 2020

CEO Letter 6 – May 2020

CEO Letter 5 – April 2019

CEO-letter 4  – November 2017

CEO-letter 3  – April 2017

CEO-letter 2  – January 2017

CEO-letter 1  – December 2016

CEO LETTER 10

As the end of 2022 approaches, Simon Grant, CEO of SciBase, summarizes the highlights that made this year extremely eventful.

CEO Letter 9

CEO-Letter 8

CEO-Letter 7

CEO-Letter 6

US progress and Nevisense Go

CEO-LETTER 5

7 April 2019 - Nevisense 3.0 and Skin Barrier application

CEO-LETTER 4

2 Nov 2017 - Updated strategy and securing our long-term capital needs

CEO-LETTER 3

April 2017 - Future trends and technologies

CEO-LETTER 2

January 2017 - Nevisense View: a new product with great potential

CEO-LETTER 1

December 2016: Teledermoscopy – good for increased awareness and access but is it good enough as a diagnostic method?

  • The Nevisense Product
    • How it works
    • How to measure
    • The EIS Technology
    • Clinical studies
    • Clinical benefits
    • Publications
  • Barrier Research
    • Skin Barrier Assessment
  • For patients
    • Skin cancer information
    • Find clinics
    • Self examination
    • Patient organizations
    • Patient Labeling
  • About Scibase
    • About Scibase
    • Available Markets
    • We are Scibase
    • News & events
    • Contact us
    • Privacy and Cookie policy
    • Cookie settings
    • Login
  • Investors
    • About Scibase
    • Press releases
    • Business model
    • Corporate Governance
    • Contact

This website uses cookies

Cookies consist of small text files. They contain data that is stored on your device. To enable us to place certain types of cookies we need to obtain your consent. At SciBase AB, corp. ID no. 556777-3899, we use the following kinds of cookies. To read more about which cookies we use and storage times, click here to access our cookies policy.

Manage your cookie-settings

Necessary cookies

Necessary cookies are cookies that must be placed for basic functions to work on the website. Basic functions are, for example, cookies which are needed so that you can use menus on the website and navigate on the site.

Cookies for statistics

For us to measure your interactions with the website, we place cookies in order to keep statistics. These cookies anonymize personal data.

Cookies for ad-tracking

To enable us to offer better service and experience, we place cookies so that we can provide relevant advertising. Another aim of this processing is to enable us to promote products or services, provide customized offers or provide recommendations based on what you have purchased in the past.